Table 1.
Clinicodemographic patient characteristics
| Factor | N (%) |
|---|---|
| Gender (n) | |
| Male | 27 (40.30%) |
| Female | 40 (59.70%) |
| Age (median, range) (y) | 53.01 (36.73–78.35) |
| Smoking history (n) | |
| No | 50 (74.63%) |
| Yes | 17 (25.37%) |
| T stage in naïve (n) | |
| 1–2 | 43 (64.18%) |
| 3–4 | 24 (35.82%) |
| TNM stage (n) | |
| IIIB-IIIC | 13 (19.40%) |
| IVA-IVB | 54 (80.60%) |
| Location (n) | |
| Upper lobe | 21 (31.34%) |
| Middle and lower lobe | 46 (68.66%) |
| Type of mutation (n) | |
| EGFR exon 19 del | 30 (44.78%) |
| EGFR exon 21 L858R | 29 (43.28%) |
| Others | 8 (11.94%) |
| Type of EGFR-TKI (n) | |
| Gefitinib | 39 (58.21%) |
| Erlotinib | 17 (25.37%) |
| Icotinib | 11 (16.42%) |
| The treatment model (n) | |
| Simultaneous EGFR-TKI and TRT for first line | 16 (23.88%) |
| Simultaneous EGFR-TKI, chemotherapy and TRT for first line | 18 (26.87%) |
| Previous chemotherapy, simultaneous EGFR-TKI and TRT for second line | 33 (49.25%) |
| Dose fractionation (n) | |
| CFRT | 59 (88.06%) |
| SBRT | 8 (11.94%) |
| Dose per fraction (median, range) (Gy) | 2 (2–12) |
| Total dose (median, range) (Gy) | 56 (39–72) |
| GTV (median, range) (ml) | 25.30 (0.70–338.80) |
| PTV (median, range) (ml) | 133.30 (11.40–752.20) |
EGFR-TKI epidermal growth factor receptor tyrosine kinase inhibitor, TRT thoracic radiotherapy, CFRT conventional fractional radiotherapy, SBRT stereotactic body radiation therapy, GTV gross tumor volume, PTV plan tumor volume, RP radiation pneumonitis